Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer’s disease (AD) and their clinical utility in predicting disease progression. Methods: pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results: Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions: pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The combination of blood GFAP and NfL has already shown promising diagnostic potential for the differentiation of FTD, AD, and controls [92]”
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, some investigators [8, 11, 14] but not others [9, 21–23] found that blood GFAP concentrations correlate with clinical markers of disease severity in participants with FTD.”
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, some studies reported elevated blood GFAP in participants with FTD compared to controls [8–18] but others observed no such GFAP increase in FTD [19–22].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring the thickness of the human cerebral cortex from magnetic resonance images
Fischl, B., & Dale, A. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200033797 · Cited by 5,818
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · cited 2×
“The pre-analytical processing protocol for blood and CSF in the SPIN cohort has been described in detail [28, 29].”
MethodClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“The participants were classified into the following clinical groups according to the internationally accepted diagnostic criteria: 72 patients with probable FTD-related clinical syndromes: 33 patients with behavioral variant of frontotemporal dementia (bvFTD) [29], 7 semantic variant of primary progressive aphasia (sv…”
MethodAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595 · cited 1×
“Emerging evidence suggests that astrocytes play an essential role in neuroinflammation and are involved in the pathophysiology of several neurological diseases [34, 36, 38].”
BackgroundClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359 · cited 4×
“In this new comparison, similar results were observed except in the comparison between FTD and CN, in which both pNfL and the combination showed higher diagnostic performance compared to this basic model MMSE, Mini-Mental State Examination; pGFAP, plasma glial fibrillary acidic protein; pNfL, plasma neurofilament ligh…”
MethodInfluentialReactive Astrocytes: Production, Function, and Therapeutic Potential
Liddelow, S. A., & Barres, B. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.006 · Cited by 2,336 · cited 1×
“Emerging evidence suggests that astrocytes play an essential role in neuroinflammation and are involved in the pathophysiology of several neurological diseases [34, 36, 38].”
BackgroundQualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 4×
“In this new comparison, similar results were observed except in the comparison between FTD and CN, in which both pNfL and the combination showed higher diagnostic performance compared to this basic model MMSE, Mini-Mental State Examination; pGFAP, plasma glial fibrillary acidic protein; pNfL, plasma neurofilament ligh…”
MethodInfluentialBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Cited by
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS
(2024) · doi:10.1038/s41591-024-02937-4 · Cited by 217
Self-citationBaiardi, S., Quadalti, C., Mammana, A., Dellavalle, S., Zenesini, C., Sambati, L., Pantieri, R., Polischi, B., Romano, L., Suffritti, M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01093-6 · Cited by 193
“Previous studies consistently documented a more significant increase in GFAP in plasma, serum, and whole blood in AD than in FTD [14, 16, 48].”
BackgroundChallenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 162
Self-citationBlood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist
Alcolea, D. A., Beeri, M. S., Rojas, J. C., Gardner, R. C., & Lleó, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207193 · Cited by 130
“High concentrations of plasma GFAP have also been reported in patients with frontotemporal lobar degeneration (FTLD)–related syndromes but to a lesser extent than those in patients with AD.(28,29)”
ResultSelf-citationO'Bryant, S. E., Petersen, M., Hall, J., Johnson, L. A., & for the HABS‐HD Study Team (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12647 · Cited by 110
Metadata
- Authors
- Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., Sala, I., Sánchez-Saudinós, M. B., Subirana, A., Videla, L., Pegueroles, J., Blesa, R., Clarimón, J., Carmona-Iragui, M., Fortea, J., Lleó, A., & Alcolea, D.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Corresponding author
- Lleó, Alberto
- Alcolea, Daniel
- ORCID
- Venue
- Translational Neurodegeneration
- Published
- 2021-12-10
- Volume
- 10
- Issue
- 1
- Pages
- 50-50
- ISSN
- 2047-9158 (ISSN-L)
- PMC
- PMC8662866
- OpenAlex
- W4200429384
- Cited by
- 86
- References
- 44
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 24 · 2023: 20 · 2022: 13
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-05-09)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Instituto de Salud Carlos III (I14/01126, PI17/01019, PI20/01473, I13/01532, PI16/01825, PI18/00335, PI18/00435, INT19/00016, PI17/01896, AC19/00103to)
- CIBERNED program (Program 1, Alzheimer Disease)
- Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408)
- Fundació la Marató de TV3 (20141210, 044412, 20142610)
- “la Caixa” Foundation (DABNI project)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- frontotemporal dementia, Alzheimer's disease, glial fibrillary acidic protein, neurofilament light chain, plasma biomarkers, differential diagnosis, cognitive decline, disease progression, astrocytes, neuroinflammation, cerebrospinal fluid biomarkers, cortical thickness
- MeSH terms
- Cross-Sectional Studies, Glial Fibrillary Acidic Protein, Humans, Intermediate Filaments, Prognosis, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. https://app.cochat.ai/papers/10.1186/s40035-021-00275-w
- The paper
- Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., Sala, I., Sánchez-Saudinós, M. B., Subirana, A., Videla, L., Pegueroles, J., Blesa, R., Clarimón, J., Carmona-Iragui, M., Fortea, J., . . . Alcolea, D. (2021). Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration. https://doi.org/10.1186/s40035-021-00275-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.